Important note: Information in this article was accurate in April 2000. The state of the art may have changed since the publication date.AIDSWEEKLY Plus; Monday, April 10, 2000
Prepared by AIDS Weekly editors from staff and other reports
The report was published in the journal Antimicrobial Agents and Chemotherapy (K. Hertogs et al., "A novel human immunodeficiency virus type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V," Antimicrob Agents Chemother 2000 Mar;44(3):568-73.
Study authors analyzed an HIV type 1 (HIV-1) mutational pattern that was associated with phenotypic resistance to lamivudine (3TC). This occurrence takes place at position 184 of reverse transcriptase, when methionine fails to replace valine (M184V), according to K. Hertogs and associates.
"Combined genotypic and phenotypic analyses of clinical isolates revealed the presence of moderate levels of phenotypic resistance (between 4- and 50-fold) to 3TC in a subset of isolates that did not harbor the M184V mutation," Hertogs et al. said.
Also, there was a significant correlation between moderate 3TC resistance and aspartic acid and alanine replacement of glutamic acid as well as isoleucine replacement of valine at reverse transcriptase residues 44 and 118, respectively, according to study data.
These replacements primarily occurred in isolates with zidovudine resistance mutations Hertogs' group noted.
The study authors confirmed their data with site-directed mutagenesis experiments.
"These data support the assumption that HIV-1 may have access to several different genetic pathways to escape drug pressure or that the increase in the frequency of particular mutations may affect susceptibility to drugs that have never been part of a particular regimen," Hertogs et al. concluded.
To see 10 additional articles on lamivudine resistance and HIV, visit www.NewsRx.com.
The corresponding author for this study is K. Hertogs, Virco NV, Gen De Wittelaan 11 B4, B-2800 Mechelen, Belgium.
Key points reported in this study are:
This article was prepared by AIDS Weekly editors from staff and other reports.
000410
AW000405
Copyright © 2000 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net
AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2000. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1990, 2000. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.